SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up – Still a Buy?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)’s share price gapped up prior to trading on Wednesday . The stock had previously closed at $13.50, but opened at $14.30. SELLAS Life Sciences Group shares last traded at $14.2540, with a volume of 2,033,316 shares trading hands.

Analyst Ratings Changes

SLS has been the topic of several recent analyst reports. Maxim Group upped their price objective on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, March 12th. Alliance Global Partners reiterated a “buy” rating on shares of SELLAS Life Sciences Group in a research note on Monday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Tuesday, April 21st. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, SELLAS Life Sciences Group currently has an average rating of “Hold” and an average price target of $10.00.

SELLAS Life Sciences Group Stock Performance

The company has a 50 day simple moving average of $8.48 and a two-hundred day simple moving average of $5.79. The firm has a market cap of $2.54 billion, a PE ratio of -56.78 and a beta of 2.42.

SELLAS Life Sciences Group (NASDAQ:SLS) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01.

Institutional Trading of SELLAS Life Sciences Group

Hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in SELLAS Life Sciences Group by 2.8% during the third quarter. Vanguard Group Inc. now owns 6,839,905 shares of the company’s stock valued at $11,012,000 after purchasing an additional 185,106 shares during the period. Anson Funds Management LP boosted its stake in shares of SELLAS Life Sciences Group by 2,093.8% in the third quarter. Anson Funds Management LP now owns 6,032,938 shares of the company’s stock worth $9,713,000 after buying an additional 5,757,938 shares during the last quarter. Geode Capital Management LLC raised its position in SELLAS Life Sciences Group by 35.9% during the fourth quarter. Geode Capital Management LLC now owns 3,077,337 shares of the company’s stock valued at $11,604,000 after acquiring an additional 812,953 shares in the last quarter. Marshall Wace LLP raised its position in SELLAS Life Sciences Group by 23,550.0% during the second quarter. Marshall Wace LLP now owns 2,715,489 shares of the company’s stock valued at $5,947,000 after acquiring an additional 2,704,007 shares in the last quarter. Finally, State Street Corp lifted its holdings in SELLAS Life Sciences Group by 60.8% in the fourth quarter. State Street Corp now owns 2,188,171 shares of the company’s stock valued at $8,249,000 after acquiring an additional 827,257 shares during the period. Institutional investors and hedge funds own 17.38% of the company’s stock.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.